UNGA 2024 and the AMR HLM:
Pre-Meeting Reports and Post-Meeting Notes

The HLM has now happened, but I am going to keep this webpage going (at least for now) as it is useful repository. Helpful post-HLM materials include the following:

  1. The 1 Oct 2024 newsletter for my review of the events at the HLM. And for those who like to listen: Hosted by Cesar Arias, Editor-in-Chief of Antimicrobial Agents and Therapy, John and Prabha Fernandes recorded a podcast discussion of the HLM
  2. CDC’s post-UNGA blog post (also available as a .pdf of their nearly identical 4 Oct 2024 post-UNGA summary email). CDC’s summary provides informative highlights from several AMR-related side-meetings. 
  3. WHO’s 4 Oct 2024 AMR email summary. In addition to just being a good tour of WHO’s diverse array of activities, it starts with a quick overview of the HLM and then points to next steps (e.g., the November 2024 Ministerial meeting in Saudi Arabia).
  4. An excellent 9 Oct 2024 blog post from Ramanan Laxminarayan’s One Health Trust that provides a very detailed summaries of several of the side events. Lots of photos, lots of summarized commentary … really gives a good sense of the meetings.
  5. This self-explanatory paper in the November 2024 issue of Open Forum Infectious Diseases: “A Global Call to Action to Fight Antimicrobial Resistance: IDSA and ESCMID Joint White Paper” by Malani, Sharland, Clancy, and Skov on behalf of the IDSA and ESCMID executive boards. https://doi.org/10.1093/ofid/ofae522.

During the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details), I thought it would be useful to have a list of major reports that had been released to inform those discussions. I am sure I am going to miss things (at least initially), so please drop me a note (john.rex@amr.solutions) if you want to see something added to this list. Thanks, —jr

  • Reports (mostly) Focused on AMR related to human health
  • Manufacturing
  • Stewardship and Access
    •  22 Mar 2021: Stewardship & Access Guide
      • From CARB-X, Wellcome, And Partners, this is the definitive guide
      • The 22 Mar 2021 newsletter is the best starting point; it also includes a video chat about the new guidelines
    • Feb 2024: Equitable & Responsible Access Roadmap
  • R&D: Push, Pull, People, and Evidence for Action
    • 07 Sep 2023: Overcoming Resistance
    • 21 Sep 2023: A New Grand Bargain to Improve the Antimicrobial Market for Human Health
      • Tackles the question of “Why would any given group take action to support an antibiotic ecosystem?” from the perspective of High-Income Countries (HICs), Low- and Middle-Income Countries (LMICs), Pharmaceutical companies, and International Organizations.
      • Webpage, report, and 5 Nov 2023 newsletter.
      • Report author: Center for Global Development (CGD)
    • 15 Nov 2023: Value and sustainability of antibiotics as essential tools for the healthcare system and people’s health
    • 08 Feb 2014: Leaving the Lab: Tracking the Decline in AMR R&D Professionals
    • 15 Feb 2024: 2024 AMR Preparedness Index Progress Report
    • 22 Feb 2024: The Economics of Antibiotic Resistance
    • 25 Mar 2024: Effective antibiotics for the Swiss health care system: today and in the future
    • 3 Apr 2024: Towards Specific Commitments and Action in the Response to Antimicrobial Resistance
    • 23 May 2024: The Lancet Series on Antimicrobial Resistance: The need for sustainable access to effective antibiotics
    • 12 Aug 2024: UK Subscription model goes live!
      • OK, it’s not a report per se but if it were it would be called “Here’s what can be done!”
      • The UK Subscription model really does set the pace for the rest of the world to follow
      • Webpage, 19 Aug 2024 newsletter
    • Aug 2024: Antibacterial pipeline trends and recommendations to enhance research and development
      • This policy brief does a good job of briefly (!) outlining 7 key points: the weak pipeline, the issues faced by developers, specific therapeutic gaps, the oral drug gap, the pediatric drug gap, the LMIC gap, and the non-traditional gap
      • Webpage, report, 1 Sep 2024 newsletter
      • Report author: WHO
    • 17 Sep 2024: Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
      •  The team behind the Global Burden of Disease (GBD) project brings us the sobering news that AMR will kill 39m during 2025-2050 unless we act!
      • Link to article and to the 17 Sep 2024 newsletter
      • Report author: GBD 2021 Antimicrobial Resistance Collaborators
    • 27 Sep 2024: Forecasting the Fallout from AMR: Economic Impacts of Antimicrobial Resistance in Humans
      • This paper makes the economic case for action and can be summarized as “Without action, AMR costs go from $66b/yr to $159b/yr by 2050.” The deep economics are not often analyzed — this paper does a great job of articulating the “pay now or pay later” perspective.
      • Article itself and to the 27 Sep 2024 newsletter
      • Report author: Center for Global Development
  • Reports (mostly) focused on agriculture and food chain
  • January 2024: Tackling Antimicrobial Resistance in Food and Agriculture
    • A global survey of actions being taken by the Quadripartite, the Global Leaders Group, and the various National Action Plans on AMR in agricultural and food systems.
    • Webpage, report, and 27 Jan 2024 newsletter.
    • Report author: FAO

During the run-up to UNGA 2024 and the HLM on AMR (15 Apr 2023 newsletter for details), I thought it would be useful to have a list of major reports. I am sure I am going to miss things (at least initially), so please drop me a note (john.rex@13.43.35.2) if you want to see something added to this list.

 

 

Last updated on

Share

The 6 meanings of “Lack of Access”

Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year delays in access to new antibiotics were common even in high income countries (19 Aug 2021 newsletter with YouTube discussion).  But as we’ll learn today, that analysis considers only one

NIAID/DMID call for antibacterials, antifungals, vaccines, & diagnostics

Dear All, Just released, the 2026 NIAID DMID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2025-1) seeks applications for projects to treat, prevent, and diagnose bacterial, fungal, and viral infections. Of interest for this community, the BAA’s Research Area 001 seeks applications by 21 Feb 2025 for bacterial and fungal projects across thee topics (see below my signature for

Sign a letter to help #PassPASTEUR!

Dear All,  MyCARE, a fungal patient advocacy organization, and the Partnership to Fight Infectious Diseases (PFID), are sending a letter to the California Congressional Delegation asking them to weigh in U.S. House and Senate leadership to pass the PASTEUR Act by the end of the year. The state of California has the largest Congressional delegation and

Global Leaders Group on AMR has vacancies!

Dear All,  The Global Leaders Group on Antimicrobial Resistance (GLG AMR) chaired by Her Excellency Prime Minister Mia Amor Mottley of Barbados is putting out a call for more members! Founded in 2020 by the Quadripartite, the GLG AMR has been fundamental to steady build of global awareness about AMR at senior political levels. One example of their impact

Scroll to Top